W
Walter A. Korfmacher
Researcher at Schering-Plough
Publications - 96
Citations - 5103
Walter A. Korfmacher is an academic researcher from Schering-Plough. The author has contributed to research in topics: Mass spectrometry & Tandem mass spectrometry. The author has an hindex of 38, co-authored 95 publications receiving 4947 citations. Previous affiliations of Walter A. Korfmacher include Applied Biosystems & Merck & Co..
Papers
More filters
Journal ArticleDOI
Direct analysis of drug candidates in tissue by matrix‐assisted laser desorption/ionization mass spectrometry
TL;DR: The anti-tumor drug SCH 226374 was unambiguously determined in mouse tumor tissue using MALDI-QqTOFMS (QSTAR) by monitoring the dissociation of the protonated drug at m/z 695.4 and images revealing the spatial localization of SCH 226 374 in tumor tissue and compound A in brain tissue were acquired.
Journal Article
Antitumor Activity of SCH 66336, an Orally Bioavailable Tricyclic Inhibitor of Farnesyl Protein Transferase, in Human Tumor Xenograft Models and Wap-ras Transgenic Mice
Ming Liu,Matthew S. Bryant,Jianping Chen,Suining Lee,Bohdan Yaremko,Phil Lipari,Michael Malkowski,Eric Ferrari,Loretta L. Nielsen,Nicholas Prioli,Janet Dell,Dineshwar Sinha,Jameel Syed,Walter A. Korfmacher,Amin A. Nomeir,C-C. Lin,Lynn Wang,Taveras Arthur G,Doll Ronald J,Njoroge F George,Alan K. Mallams,Stacy W. Remiszewski,Joseph J. Catino,Viyyoor M. Girijavallabhan,Paul Kirschmeier,W. Robert Bishop +25 more
TL;DR: Sch 66336 as mentioned in this paper is a small molecule farnesyl protein transferase inhibitor that shares a common tricyclic nucleus and compete with peptide/protein substrates for binding to the Farnesyl Protein Transferase.
Journal ArticleDOI
Investigation of matrix effects in bioanalytical high-performance liquid chromatography/tandem mass spectrometric assays: application to drug discovery
Hong Mei,Yunsheng Hsieh,Cymbylene Nardo,Xiaoying Xu,Shiyong Wang,Kwokei Ng,Walter A. Korfmacher +6 more
TL;DR: This report demonstrates that matrix effects can also be caused by exogenous materials, such as polymers contained in different brands of plastic tubes, or Li-heparin, a commonly used anticoagulant, and finds the APCI mode to be more sensitive to matrix effects than the ESI mode.
Journal ArticleDOI
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection
Srikanth Venkatraman,Stephane L. Bogen,Ashok Arasappan,Frank Bennett,Kevin X. Chen,Edwin Jao,Yi-Tsung Liu,Raymond G. Lovey,Hendrata Siska,Yuhua Huang,Weidong Pan,Parekh Tejal N,Patrick Pinto,Veljko Popov,Pike Russell E,Sumei Ruan,Santhanam Bama,Bancha Vibulbhan,Wanli Wu,Weiying Yang,Jianshe Kong,Xiang Liang,Jesse Wong,Rong Liu,Nancy Butkiewicz,Robert Chase,Andrea Hart,Sony Agrawal,Paul Ingravallo,John Pichardo,Rong Kong,Bahige M. Baroudy,Bruce A. Malcolm,Zhuyan Guo,Andrew Prongay,Vincent Madison,Lisa Broske,Xiaoming Cui,Kuo-Chi Cheng,Yunsheng Hsieh,Jean-Marc Brisson,Danial Prelusky,Walter A. Korfmacher,Ronald E. White,Susan Bogdanowich-Knipp,Pavlovsky Anastasia,Prudence Bradley,Anil K. Saksena,Ashit K. Ganguly,Piwinski John J,Viyyoor M. Girijavallabhan,F. George Njoroge +51 more
TL;DR: The SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described.
Journal ArticleDOI
Foundation review: Principles and applications of LC-MS in new drug discovery
TL;DR: A summary of the key components of HPLC-MS systems, as well as an overview of major application areas that use this technique as part of the drug discovery process, will be described here.